Studeni 2021: Nedavno je počelo prvo kliničko ispitivanje južnokorejske domaće terapije kimernim antigenskim receptorom T (CAR-T) sljedeće generacije, koja je dizajnirana za zaobilaženje signala imunoloških kontrolnih točaka.
Korejski napredni institut za znanost i tehnologiju (KAIST) objavio je u srijedu da se faza 1b kliničkog ispitivanja njegove CAR-T stanične terapije trenutno provodi u Samsungovom medicinskom centru u Seulu. Ispitivanje se provodi s 10 korejskih pacijenata koji su imali recidiv i refraktorni difuzni B-velikostanični limfom. Marketinška prava za naftovod prenesena su sa sveučilišta na tvrtku Curocell, čiji je suosnivač profesor Kim Chan-hyuk. Curocell je zadužen za klinički razvojni program revolucionara imunoterapija.
In addition, a Phase 2 kliničko ispitivanje involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for receptor himernog antigena T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Možda biste voljeli pročitati: CAR T-Cell terapija u Koreji
Nalazi studije predstavljeni su u članku koji je objavljen na internetu u listopadskom broju časopisa Molecular Therapy.
